KPTI
Karyopharm·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KPTI fundamentals
Karyopharm (KPTI) released its earnings on Nov 3, 2025: revenue was 44.04M (YoY +13.52%), beat estimates; EPS was -3.82 (YoY -1369.23%), missed estimates.
Revenue / YoY
44.04M
+13.52%
EPS / YoY
-3.82
-1369.23%
Report date
Nov 3, 2025
KPTI Earnings Call Summary for Q3,2025
- Phase III SENTRY Trial Milestone: Enrollment complete, targeting March 2026 readout with 79% SVR35 vs. 35% for ruxolitinib alone.
- Revenue Growth: Q3 2025 total revenue $44M (+13% YoY), XPOVIO net product revenue $32M (+8.5% YoY).
- $1B Myelofibrosis Opportunity: 75% physician intent for combination therapy in 4,000 new U.S. patients/year.
- Financial Flexibility: $100M refinancing extends cash runway to Q2 2026, with no additional sales force needed.
- Safety Profile: Combination therapy shows 26% Grade 3+ anemia vs. 37% for ruxolitinib, 5-7% discontinuation rate.
EPS
Revenue
Revenue & Expenses
KPTI has released its 2025 Q3 earnings report, with revenue of 44.04M, reflecting a YoY change of 13.57%, and net profit of -33.13M, showing a YoY change of -3.29%. The Sankey diagram below clearly presents KPTI's revenue sources and cost distribution.
Key Indicators
Karyopharm (KPTI) key financial stats and ratios, covering profitability, financial health, and leverage.
Karyopharm (KPTI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Karyopharm (KPTI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Karyopharm (KPTI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Karyopharm (KPTI) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Karyopharm (KPTI) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What guidance did Karyopharm's management provide for the next earnings period?What is Karyopharm's gross profit margin?What were the key takeaways from Karyopharm's earnings call?What is Karyopharm's latest dividend and current dividend yield?What is the revenue and EPS growth rate for Karyopharm year over year?What is the market's earnings forecast for Karyopharm next quarter?What factors drove the changes in Karyopharm's revenue and profit?What were the key takeaways from Karyopharm’s earnings call?
